We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

15 hedge funds and large institutions have $4.32M invested in Moleculin Biotech in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital inflows, than outflows

Capital inflows: $81.5K | Capital outflows: $66.5K

0.08% more ownership

Funds ownership: 10.34% → 10.42% (+0.08%)

6% less funds holding

Funds holding: 16 → 15 (-1)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$46.5K
2
JMAC Enterprises
JMAC Enterprises
Pennsylvania
+$23.3K
3
Charles Schwab
Charles Schwab
California
+$11.6K

Top Sellers

Rank Fund Capital Flow
1
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$19K
2
Northern Trust
Northern Trust
Illinois
-$11.6K
3
Sio Capital Management
Sio Capital Management
New York
-$11.6K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$11.6K
5
Wells Fargo
Wells Fargo
California
-$11.6K

MBRX Hedge Fund Activity: Q2 2022 in Review

15 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2022, worth a combined $4.32M — down 18% from $5.26M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of MBRX and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $46.5K. The largest seller was Envestnet Asset Management, exiting entirely with an estimated $19K sold.

  • 15 institutional investors held Moleculin Biotech (MBRX) as of Q2 2022, down from 16 in Q1 2022.
  • Funds reported $4.32M of Moleculin Biotech stock for Q2 2022, down 18% quarter-over-quarter.
  • 1 fund opened new Moleculin Biotech positions in Q2 2022 and 2 closed out, a net change of -1 holder.
  • The largest Moleculin Biotech buyer in Q2 2022 was Renaissance Technologies, an estimated $46.5K added.
  • The largest Moleculin Biotech seller in Q2 2022 was Envestnet Asset Management, an estimated $19K sold.

Based on aggregated 13F filings for Q2 2022.